{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T13:19:24Z","timestamp":1665062364424},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,22]],"date-time":"2017-10-22T00:00:00Z","timestamp":1508630400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40268-017-0213-9","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T18:27:31Z","timestamp":1508783251000},"page":"623-629","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline"],"prefix":"10.1007","volume":"17","author":[{"given":"Marco D.","family":"Huesch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,22]]},"reference":[{"issue":"19","key":"213_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008\u201314. doi:\n                        10.1001\/jama.2015.15629\n                        \n                    .","journal-title":"JAMA"},{"issue":"14","key":"213_CR2","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jama.2012.423","volume":"307","author":"RF Redberg","year":"2012","unstructured":"Redberg RF, Katz MH. Healthy men should not take statins. JAMA. 2012;307(14):1491\u20132. doi:\n                        10.1001\/jama.2012.423\n                        \n                    .","journal-title":"JAMA"},{"issue":"19","key":"213_CR3","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2016.15450","volume":"316","author":"US Preventive Services Task Force","year":"2016","unstructured":"US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997\u20132007. doi:\n                        10.1001\/jama.2016.15450\n                        \n                    .","journal-title":"JAMA"},{"issue":"19","key":"213_CR4","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1001\/jama.2016.15085","volume":"316","author":"RF Redberg","year":"2016","unstructured":"Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA. 2016;316(19):1979\u201381. doi:\n                        10.1001\/jama.2016.15085\n                        \n                    .","journal-title":"JAMA"},{"key":"213_CR5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pds.1341","volume":"16","author":"DL McClure","year":"2007","unstructured":"McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf. 2007;16:132\u201343.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"213_CR6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359:248\u201352.","journal-title":"Lancet"},{"key":"213_CR7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/sim.4780100417","volume":"10","author":"DP Byar","year":"1991","unstructured":"Byar DP. Problems with using observational databases to compare treatments. Stat Med. 1991;10:663\u20136.","journal-title":"Stat Med"},{"issue":"6","key":"213_CR8","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1097\/MLR.0b013e3181dbebe3","volume":"48","author":"MA Brookhart","year":"2010","unstructured":"Brookhart MA, Sturmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6):S114\u201320.","journal-title":"Med Care"},{"key":"213_CR9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","volume":"63","author":"JL Bosco","year":"2010","unstructured":"Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63:64\u201374.","journal-title":"J Clin Epidemiol"},{"key":"213_CR10","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532\u201361.","journal-title":"Lancet"},{"key":"213_CR11","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.","journal-title":"BMJ"},{"key":"213_CR12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758\u201369.","journal-title":"J Clin Lipidol"},{"issue":"10088","key":"213_CR13","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","volume":"389","author":"A Gupta","year":"2017","unstructured":"Gupta A, Thompson D, Whitehouse A, on behalf of the ASCOT Investigators, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase (published online May 2). Lancet. 2017;389(10088):2473\u201381. doi:\n                        10.1016\/S0140-6736(17)31075-9\n                        \n                    .","journal-title":"Lancet"},{"key":"213_CR14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.111.189381","volume":"59","author":"AJ Stears","year":"2012","unstructured":"Stears AJ, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934.","journal-title":"Hypertension"},{"key":"213_CR15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.112.192542","volume":"59","author":"WJ Elliott","year":"2012","unstructured":"Elliott WJ. Effects of potassium-sparing versus thiazide diuretics on glucose tolerance: new data on an old topic. Hypertension. 2012;59:911.","journal-title":"Hypertension"},{"key":"213_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1524-6175.2005.04679.x","volume":"8","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis PA, Bakris GL. Do the metabolic effects of \u03b2 blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens. 2006;8:351\u20136. doi:\n                        10.1111\/j.1524-6175.2005.04679.x\n                        \n                    .","journal-title":"J Clin Hypertens"},{"issue":"2","key":"213_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","volume":"172","author":"AL Culver","year":"2012","unstructured":"Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women\u2019s Health Initiative. Arch Intern Med. 2012;172(2):144\u201352.","journal-title":"Arch Intern Med"},{"key":"213_CR18","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"The SPRINT Research Group","year":"2015","unstructured":"The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"213_CR19","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. \n                        http:\/\/circ.ahajournals.org\/content\/circulationaha\/early\/2013\/11\/11\/01.cir.0000437741.48606.98.full.pdf\n                        \n                    . Accessed 1 Sept 2017."},{"issue":"suppl","key":"213_CR20","doi-asserted-by":"crossref","first-page":"27C","DOI":"10.1016\/j.amjcard.2005.12.007","volume":"97","author":"M Bottorff","year":"2006","unstructured":"Bottorff M. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(suppl):27C\u201331C.","journal-title":"Am J Cardiol"},{"key":"213_CR21","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1377\/hlthaff.24.6.1571","volume":"24","author":"RA Hayward","year":"2005","unstructured":"Hayward RA, Kent DM, Vijan S, et al. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood). 2005;24:1571\u201381.","journal-title":"Health Aff (Millwood)"},{"key":"213_CR22","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","volume":"357","author":"R Wang","year":"2007","unstructured":"Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine\u2014reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189\u201394.","journal-title":"N Engl J Med"},{"issue":"12","key":"213_CR23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jama.2016.2420","volume":"315","author":"H Bauchner","year":"2016","unstructured":"Bauchner H, Golub RM, Fontanarosa PB. Data sharing: an ethical and scientific imperative. JAMA. 2016;315(12):1238\u201340.","journal-title":"JAMA"},{"key":"213_CR24","unstructured":"National Heart Lung and Blood Institute. Biologic Specimen and Data Repository Information Coordinating Center. Action to Control Cardiovascular Risk in Diabetes (ACCORD). \n                        https:\/\/biolincc.nhlbi.nih.gov\/studies\/accord\/?q=ACCORD\n                        \n                    . Accessed 1 Sept 2017."},{"key":"213_CR25","unstructured":"New England Journal of Medicine. Call for Entries: SPRINT Data Analysis Challenge. \n                        https:\/\/challenge.nejm.org\/pages\/home?emp=marcom&utm_source=nejmlist&utm_medium=email&utm_campaign=challenge_awareness&utm_content=activesub\n                        \n                    . Accessed 1 Sept 2017."},{"issue":"19","key":"213_CR26","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/jama.2016.16557","volume":"316","author":"PD Thompson","year":"2016","unstructured":"Thompson PD. What to believe and do about statin-associated adverse effects. JAMA. 2016;316(19):1969\u201370. doi:\n                        10.1001\/jama.2016.16557\n                        \n                    .","journal-title":"JAMA"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-017-0213-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T05:36:22Z","timestamp":1510983382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-017-0213-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,22]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["213"],"URL":"https:\/\/doi.org\/10.1007\/s40268-017-0213-9","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,22]]}}}